Expression of mdm-2 protein in neoplastic, preneoplastic, and normal bronchial mucosa specimens: Comparative study with p53 expression

Hybridoma

Volumn 17, Issue 4, 1998, Pages 339-345

  Rasidakis, Antonios ^a   Orphanidou, Dora ^a   Kalomenidis, John ^a   Papamichalis, George ^b   Toumbis, Michael ^a   Lambaditis, John ^a   Sacharidou, Anastasia ^a   Papastamatiou, Hera ^b   Jordanoglou, John ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0031691055     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1998.17.339     Document Type: Article

References (60)

1. Vialet J, and Minna ID: Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer. Am J Resp Cell Mol Biol 1990;2:225-232.
2. Greenblatt MS, Bennett WP, and Hollstein Mand Harris CC: Mutations in the p53 tumour suppressor gene. Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
3. Chen PL, Chen Y, Bookstain R, and Lee WH: Genetic mechanism of tumour suppression by the human p53 gene. Science 1990;250: 1576-1579.
4. Iggo R, Gatter K, Bartek, Lane D, and Haris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;355:675-679.
5. Reihsaus E, Kohler M, Kraiss S, Oren M, and Montenarh M: Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 1990;5:137-145.
6. Rotter V, Aloni-Grinstein R, Schwartz D, Elkind NB, Somons A, Wolkowicz R, Lavigne M, Beserman P, Kapon A, and Goldfinger N: Does wild-type p53 play a role in normal cell differentiation? Cancer Biol 1994;5:229-236.
7. Ozbun MA, and Butel JS: Tumour suppressor p53 mutations and breast cancer: A critical analysis. Cancer Res 1995;60:71-141.
8. Li X, Tsuji T, Wen S, Sobhan F, Wang Z, and Shinozaki F: Cytoplasmic expression of p53 protein and its morphological features in salivary gland lesions. J Oral Pathol Med 1995;24:201-205.
9. Kerr MK, Carey AF, King G, and Lamb D: Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53 and c-erb-2 expression. J Pathol 1994;174:249-256.
10. Rogel A, Popliker M, Webb GL, and Oren M: p53 cellular tumor antigen: Analysis of mRNA levels in normal cell adult tissues embryos and tumors. Mol Cell Biol 1985;5:2851-2855.
11. Lane DP: p53, guardian of the genome. Nature 1992;358:15-16.
12. Perry ME, and Levine AJ: Tumour suppressor p53 and the cell cycle. Curr Opin Genet Dev 1993;3:50-54.
13. Camman CE, and Kastan MB: Induction of apoptosis by tumour suppressor genes and oncogenes. Semin Cancer Biol 1995;6:17-25.
14. Vogelstien B: A deadly inheritance. Nature 1990;348:681-682.
15. Levine AJ: The p53 tumour suppressor gene. New Engl J Med 1992;326:1350-1352.
16. Fontanini G, Vignati S, Bigini D, Merlo GR, Ribecchini A, Angeletti CA, Basolo F, Pingitore R, and Bevilacqua G: Human non-small cell lung cancer: p53 protein accumulation is an early event and persist during metastatic progression. J Pathol 1994;174:23-31.
17. Brambilla E, Gazzeri S, Moro D, Caron de Fromentel C, Gouyer V, Jacrot M, and Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993;143:199-210.
18. Top B, Mooi W, Klaver SG, Boerrigter L, Wisman P, Elbers HR, Visser S, and Rodenhuis S: Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 1995;64:83-91.
19. Klein N, Vignaud JM, Sadmi M, Plenat F, Borelly J, Duprez A, Martinet Y, and Martinet N: Squamous metaplasia expression of proto-oncogenes and p53 in lung cancer patients. Lab Invest 1993;68:26-32.
20. Gazzeri S, Brambilla E, Caron De Fromentel C, Gouyer V, Moro D, Perron P, Bercer F, and Brambilla C: P53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 1994;58:24-32.
21. Lohman D, Putz B, Reich U, Bohm J, Prauer H, and Hofler H: Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 1993;142:907-915.
22. Fontanini G, Bigini D, Vignati S, Macchiarini P, Pepe S, Angeletti A, Pingitore R, and Squartini F: p53 expression in non small cell lung cancer: Clinical and biological correlations. Anticancer Res 1993;13:737-742.
23. Boers JE, Ten Velde GPM, and Thunnissen FB: p53 in squamous metaplasia: A marker for risk of respiratory tract carcinoma. Am J Respir Crit Care Med 1996;153:411-416.
24. Hirano T, Franzen B, Kato H, Ebihara Y, and Auer G: Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy and p53 expression. Am J Pathol 1994;144:296-301.
25. Bennett W, Colby T, Travis W, Borkowski A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, Vahakangas KH, Soini Y, Paakko P, Welsh JA, Trump BF, and Harris CC: P53 protein accumulation frequently in early bronchial neoplasia. Cancer Res 1993;53:4817-4822.
26. Westra WH, Offerhaus GJA, Goodman SN, Slebos RJC, Polak M, Baas IO, Rodenhuis S, and Hruban HR: Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993;17:213-220.
27. Pavelic ZP, Gluckman JL, Gapany M, Raising J, Craven JM, Kelley DJ, Pavelic L, Gapany S, Biddinger P, and Stambrook JP: Improved immunohistochemical detection of p53 protein in paraffin-embedded tissues reveals elevated levels in most head and neck and lung carcinomas: Correlation with clinicopathological parameters. Anticancer Res 1992;12:1389-1394.
28. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, and Gatter CK: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992;66:735-738.
29. Martinez JC, Mateo M, Sanchez-Beato M, Villuendas R, Orradre LJ, Algara P, Sanchez-Verde L, Garcia P, Lopez C, Martinez P, and Piris A: MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol 1995;77:27-34.
30. Cordon-Cardo C, Latres E, Drobnjak M, Oliva RM, Pollack D, Woodruff MJ, Marechal V, Chen J, Brennan FM, and Levine JA: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799.
31. Lane DP, and Crawford LV: T-antigen is bound to host protein in SV40-transform cells. Nature 1979;278:261-263.
32. Sarnow P, Ho YS, Williams J, and Levine AJ: Adenovirus EIB-58Kd tumour antigen and SV40 large tumour antigen are physically associated with the same 54Kd cellular protein in transformed cells. Cell 1982;28:387-394.
33. Wemess BA, Levine AJ, and Howley PM: The E6 proteins encoded by human papillovirus type 16 and 18 can complex p53 in vitro. Science 1990;248:76-79.
34. Yew PR, and Berk AJ: Inhibition of 53 transactivation required for transformation by adenovirus early IB protein. Nature 1992;357: 82-85.
35. Mietz JA, Unger T, Huibregtse JM, and Howley PM: The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by PV-16 E6 oncoprotein. EMBO J 1992;11:5013-5020.
36. Takhaezadeh SS, Trusko SP, and George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumour cell line. EMBO J 1991;10:1565-1569.
37. Momand J, Zambetti GP, Olson DG, George DL, and Levine AJ: The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 1992;69:1237-1245.
38. Cahilly-Snyder L, Yang-Feng T, Francke U, and George DL: Molecular analysis and chromosomal mapping of amplified genes isolated from a transform mouse 3T3 cell line. Somatic Cell Mol Genet 1987;13:235-244.
39. Fakharzadeh SS, Trusko SP, and George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumour cell line. EMBO J 1991;10:1565-1569.
40. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, and Vogelstein B: Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857-860.
41. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, and Dervan PA: Amplification of the mdm2 gene in human breast cancer and its association with mdm2 and p53 protein status. Br J Cancer 1995;71:981-985.
42. Hinds PW, Finlay CA, Guartin RS, et al.: Mutant p53 cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells. Cell Growth Diff 1990;1:571-580.
43. Barak Y, and Oren M: Enhanced binding of a 95 kD protein in p53 in cells undergoing p53-mediated growth arrest. EMBO J 1992;11:2115-2121.
44. Maestro R, Gloghini G, Doglioni C, Gasparotto D, Vukosavljevic T, De Re V, Laurino L, Carbone A, and Biocchi M. MDM2 overexpression does not account for stabilisation of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 1995;85:3239-3246.
45. World Health Organization. The histological typing of lung tumors. Am J Clin Pathol 1982;77:123-136.
46. Hsu SM, Raine L, and Fanger H: The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: Comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
47. Marx J. How p53 suppresses cell growth. Science 1993;262: 1644-1645.
48. Harris CC, and Hollstein M: Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-1327.
49. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992;71:543-546.
50. Barak Y, Juven T, Haffner R, Oren M, and Oren R: MDM2 expression is induced by wild-type p53 activity. EMBO J 1993;12:461-468.
51. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti AC, and Bevilacqua G: mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 1995;4:93-97.
52. Girod CS, Cesarz D, Fischer U, and Krueger RFG: Detection of p53 and mdm2 protein expression in head and neck carcinogenesis. Anticancer Res 1995;15:1453-1458.
53. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G, and Barbareschi M: mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995;175:31-38.
54. Ginsberg RJ, Kris MG, and Armstrong JG: Cancer of the lung. In: Cancer, Principles and Practice of Oncology. De Vita VT, Rosenberg S, Hellman S (eds.). JB Lippincott Co., Philadelphia, 1993, pp. 673-723.
55. Kashii T, Mizushima Y, Lima C, Noto H, Sato H, Saito H, Kusajima Y, Kitagawa M, Sugiyama S, and Kobayashi M: Evaluation of prognostic significance of p53 gene alterations in patients with surgically resected lung cancer. J Oncol 1995;6:123-128.
56. Mitsudomi T, Lam S, Shirakusa T, and Gazdar AF: Detection and sequencing of p53 gene mutation in bronchial biopsy samples in patients with lung cancer. Chest 1993;104:362-365.
57. Sozzi G, Miozzo M, Pastorino U, Pilotti S, Donghi R, Giarole M, Gregorio L, Manenti G, Radice P, Minoletti F, Della Porta G, and Pierotti AM: Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res 1995;55:135-140.
58. Slaughter DP, Southwick HW, and Smejkal W: Field cancerization in oral stratified squamous epithelium. Cancer (Philadelphia) 1953;6:693-698.
59. Landers JE, Haines DS, Strauss JF, and George LD: Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9:2745-2750.
60. Wiethege T, Voss B, and Mueller KN: Detection of mdm2 protooncogene in paraffin embedded human bronchial and epithelium. J Cancer Res Clin Oncol 1994;120:458-466.